KalVista Pharmaceuticals, Inc. (KALV) Thursday reported higher loss for the second quarter, on higher research and development expenses. The loss was wider than expected.
Quarterly loss widened to $27.7 million or $0.80 per share from $22.3 million or $0.90 per share last year.
On average, five analysts polled by Thomson Reuters had expected a loss of $0.79 per share for the quarter. Analysts' estimates typically exclude special items.
The company reported no revenues for the period.
On Wednesday, KalVista shares closed at $8.97, up 0.56% on the Nasdaq.
For comments and feedback: editorial@rttnews.com